ILIAS Biologics ILIAS Therapeutics

(주)셀렉스라이프사이언스

R & D

ILIAS is the Leader of Next-Generation Exosome Therapeutics.

Pipeline

Our proprietary technology, EXPLORTM, has high potential for
application to indefinite pipelines depending on cargo proteins.

Distinctive Features of the Pipelines

  • 01

    Active protein
    loading

    Capable of protein loading
    in/outer surface of exosome

  • 02

    Penetration to
    Blood-Brain Barrier

    Capable of treating neurological disorders

  • 03

    Enhanced stability
    within blood

    Improved Drug stability
    & delivery efficiency

Pipeline Overview

Sepsis(First-in-Class)

  • High efficacy in short-term
  • Exosomes stably deliver their anti-inflammatory cargo protein to the target
    cells since they’re protected by bi-lipid membrane enclosure
  • Exosomes have high biocompatibility compared to artificial nanoparticles

Preterm Labor(First-in-Class)

  • Exosomes directly deliver drugs to the fetus and fetal tissues of the uterine
    cavity because they can penetrate the placental barrier between mother
    and fetus

Gaucher’s Disease(Best-in-Class)

  • High percentage of the exosomes are delivered to liver and spleen
  • Certain percentage of exosomes from the specific cells penetrates
    Blood-Brain Barrier(BBB)
    • Modification of surface protein X of the exosomes increases penetration
      rate (Type 2 & 3 Gaucher’s Disease)
Pipelines in Progress

Pipeline

Publication

TOP

개인정보취급방침

닫기

이메일주소무단수집거부

닫기

사이트맵

사이트맵

몬트리올의정서
국내이행법령
사업안내
특정물질 수출입
알림·자료실
민원서비스
닫기